Cell Vitals ‘Revolution’ Quelled? FDA Warns About Stem-Cell Claims
This article was originally published in The Tan Sheet
Executive Summary
Claims promoting Cell Vitals’ ReLuma skin care line render the products unapproved drugs, FDA says. Marketed as “A Revolution in Stem Cell Skin Care,” the products feature cytokines and growth factors harvested from adult stem cells that send “grow and divide” signals to aging skin cells, the firms says.
You may also be interested in...
Rash Of FDA Warning Letters Raises Questions For Cosmetics Industry
EAS Consulting rep John Bailey, who directed FDA’s cosmetics program in the 1990s and served as PCPC chief scientist through July of 2011, offers his view on the six warning letters issued to cosmetics firms between Sept. 7 and Oct. 5. It’s too early to say whether FDA is taking a more aggressive stance on cosmetics claims, but firms “need to be aware,” Bailey says.
FDA Warns Lancome For Gene/Stem-Cell Claims: A Signal To Marketplace?
Claims for L’Oreal’s Lancome brand’s Genifique anti-aging line identify the products as drugs, FDA says. The agency cites claims that the brand’s technology “boosts the activity of genes” and “has been shown to improve the condition” around stem cells – language not unique in the anti-aging cosmeceutical market.
Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat
Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.